Abstract
In conventional cardiac surgery, use of cardiopulmonary bypass (CPB) initiates a series of events best-characterized as a “whole body inflammatory response,” with activation of coagulation, fibrinolysis, and inflammatory cascades (1–3). Perturbation and activation of the endothelium are central in this response (4–6). However, with the emergence of minimally invasive techniques that allow coronary artery bypass grafts to be performed on a beating heart without CPB, it is likely that diminished acute systemic endothelial activation will result.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Colman RW. Hemostatic complications of cardiopulmonary bypass. Am J Hematol 1995; 48: 267–272.
Edmunds HL. Why cardiopulmonary bypass makes patients sick: strategies to control the blood synthetic surface interaction. Adv Cardiac Surg 1996; 6: 131–167.
Boyle EM Jr, Pohlman TH, Johnson MC, Verrier ED. The systemic inflammatory response. Ann Thorac Surg 1997; 64: S31 - S37.
Verrier ED, Boyle EM Jr. Endothelial injury in cardiovascular surgery: an overview. Ann Thorac Surg 1997; 64: S2 - S8.
Davies MG, Hagen PO. The vascular endothelium: a new horizon. Ann Surg 1993; 218: 593–609.
Vane JR, Anggard EE, Botting RM. Regulatory functions of the vascular endothelium. N Engl J Med 1990; 323: 27–36.
Ross R. Cell biology of atherosclerosis. Annu Rev Physiol 1995; 57: 791–804.
Luscher TF. Vascular biology of coronary artery bypass grafts. Coronary Artery Dis 1992; 3: 157–65.
Harlan J. Leukocyte-endothelial interactions. Blood 1985: 65: 513–525.
Pober JS, Cotran RS. Cytokines and endothelial cell biology. Physiol Rev 1990; 70: 427–451.
Bevilacqua MP, Pober JS, Wheeler ME, Cotran RS, Gimbrone MA Jr. Interleukin-1 activation of vascular endothelium: effects on procoagulant activity and leukocyte adhesion. Am J Pathol 1985; 121: 394–403.
Bevilacqua MP, Pober JS, Majeau GR, Fiers W, Cotran RS, Gimbrone MA Jr. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparisons with the actions of interleukin 1. Proc Natl Acad Sci USA 1986; 83: 4533–4537.
Kourembanas S, Marsden PA, McQuillan LP, Faller DV. Hypoxia induces endothelial cell gene expression and secretion in cultured human endothelium. J Clin Invest 1991; 88: 1054–1057.
Selke FW, Boyle EM Jr, Verrier ED. The pathophysiology of vasomotor dysfunction. Ann Thorac Surg 1997; 64: S9 - S15.
Billar TR. Nitric oxide: novel biology with clinical relevance. Ann Surg 1995; 221: 339–349.
Luscher TF, Tanner FC, Tschundi MR, Noll G. Endothelial dysfunction in coronary artery disease. Annu Rev Med 1993; 44: 395–418.
Boyle EM Jr, Pohlman TH, Cornejo CJ, Verner ED. Ischemia-reperfusion injury. Ann Thorac Surg 1997; 64: S24 - S30.
Kubes P, Suzuki M, Granger DN. Nitric oxide, and endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 1991; 88: 4651–4655.
Davie EW, Fumikawa K, Kisiel W. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 1991;30:10, 363–10, 370.
Stern DM, Espisito C, Gerlach H, et al. Endothelium and regulation of coagulation. Diabetes Care 1991; 14: 160–166.
Boyle EM Jr, Verrier ED, Spiess BD. The procoagulant response to injury. Ann Thorac Surg 1997; 64:S 16 - S23.
Esmon CT. The role of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 1989; 264: 4743–4746.
Esmon NL. Thrombomodulin. Prog Hemost Thromb 1989; 9: 29–55.
Sakata Y, Curriden S, Lawrence D, et al. Activated protein C stimulates fibrinolytic activity of cultured endothelial cells and decreases antiactivator activity. Proc Natl Acad Sci USA 1985; 82: 1121–1125.
Lucore C. Regulation of fibrinolysis by vascular endothelium. Coronary Artery Dis 1991; 2: 157–166.
Emeis JJ, Kooistra T. Interleukin-1 and lipopolysaccharide induces and inhibitor of tissue type plasminogen activator in vivo and in cultured endothelial cells. J Exp Med 1986; 163: 1260–1266.
Nachman RL, Hajjar KA, Silverstein RL, Dinarello CA. Interleukin 1 induces endothelial synthesis of plasminogen activator inhibitor. J Exp Med 1988; 163: 1595–1600.
Hanss M, Collen D. Secretion of tissue type plasminogen activator and plasminogen activator inhibitor by cultured human endothelial cells: modulation by thrombin, endotoxin, and histamine. J Lab Clin Med 1987; 109: 97–104.
Tanaka K, Takao M, Yaka I, et al. Alterations in coagulation and fibrinolysis associated with cardiopulmonary bypass during open heart surgery. J Cardiothorac Anesth 1989; 3: 181–188.
Chandler WL, Fitch JC, Wall MH, et al. Individual variations in the fibrinolytic response during and after cardiopulmonary bypass. Thromb Hemost 1995; 74: 1293–1297.
Santos MT, Valles J, Marcu-AJ, et al. Enhancement of platelet reactivity and modulation of eicosanoid production by intact erythrocytes. J Clin Invest 1991; 87: 571–580.
Rinder CS, Bohnert J, Rinder HM, et al. Platelet activation and aggregation during cardiopulmonary bypass. Anesthesiology 1991; 75: 388–393.
Weyrich AS, Ma XY, Lefer DJ et al. In vivo neutralization of p-selectin protects feline hearts and endothelium in myocardial ischemia and reperfusion injury. J Clin Invest 1993; 991: 2620–2629.
McEver RP, Beckstead JH, Moore KL, et al. GMP 140, a platelet alpha granule membrane protein, is also synthesized by vascular endothelial cells and is localized in Wiebel Palade bodies. J Clin Invest 1989; 84: 92–99.
Marzocchi A, Piovaccari G, Marrozzini C, Ortolanii P, Palmerini T, Branzi A, Magnani B. Results of coronary stenting for unstable vs. stable angina pectoris. Am J Cardiol 1997; 79: 1314–1318.
Chambers CE, Kozak M, Ettinger SM, Gilchrist IC. Interventional cardiology: present and future. J Cardiothorac Vasc Anesth 1997; 11 (2): 211–219.
Van der Giessen WJ, Serruys PW, Visser WJ, et al. Endothelialization of intravascular stents. J Int Cardiol 1988; 1: 109–120.
Zubaid M, Penn IM, Buller CE, Moscovich MD, Ricci DR, Chauhan A. Antiplatelet therapy alone is safe and effective after coronary stenting: observations of a transition in practice. Can J Cardiol 1997; 13 (4): 335–340.
Berger PB, Holmes DR Jr, Ohman EM, et al. Restenosis, reocclusion and adverse cardiovascular events after successful balloon angioplasty of occluded versus non occluded coronary arteries: results from the multicenter American research trial with cilazapril after angioplasty to prevent transluminal coronary obstruction and restenosis (MARCATOR). J Am Coll Cardiol 1996; 27: 1–7.
The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with Tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997; 96: 1445–1453.
Kleiman NS. Primary and secondary safety endpoints from IMPACT II. Am J Cardiol 1997; 80 (4A): 29B - 33B.
Schror K. Antiplatelet drugs. Drugs 1995; 50: 7–28.
Hobson AG, Sowinski KM. Ticlodipine and aspirin following implantation of coronary stents. Ann Pharmacol 1997; 31: 770–772.
Coller BS. Platelets and thrombolytic therapy. N Engl J Med 1990; 322: 33–42.
Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995; 332: 1553–1559.
Simons M, Leclerc G, Safian RD, et al. Relation between activated smooth muscle cells in coronary artery lesions and restenosis after atherectomy. N Engl J Med 1993; 328: 608–613.
Raines EW, Dover SK, Ross R. Interleukin-1 mitogenic activity for fibroblasts and smooth muscle cells is due to PDGF-AA. Science 1989; 243: 393–396.
Allaire E, Clowes AW. The intimal hyperplastic response. Ann Thorac Surg 1997; 64: S38–S46.
Schwartz SM, deBlois D, Obrian ER. The intima: soil for atherosclerosis and restenosis. Circ Res 1995; 77: 445–465.
Gay CG, Winkles JA. Interleukin-1 regulates heparin-binding growth factor 2 gene expression in vascular smooth muscle cells. Proc Natl Acad Sci USA 1991; 88: 296–300.
Clowes AW. Prevention and management of recurrent disease after arterial reconstruction: new prospects of pharmacologic control. Thromb Hemost 1991; 66: 2–66.
Unterburg C, Sandrock D, Nebendahl K, Buchwald AB. Reduced acute thrombus formation results in decreased neointimal proliferation after coronary angioplasty. J Am Coll Cardiol 1995; 26: 1747–1754.
Boyle EM, Lille ST, Allaire E, Clowes AW, Verrier ED. Atherosclerosis. Ann Thorac Surg 1997; 64: S47–S56.
Cybulsky MI, Gimbrone MA Jr. Endothelial cell expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 1991; 251: 788–791.
Galis ZS, Sukhova GK, Kranzhofer R, et al. Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. Proc Natl Acad Sci USA 1994; 94: 402–406.
Velican D, Velican C. Intimai thickening in developing coronary arteries and its relevance to atherosclerotic involvement. Atherosclerosis 1976; 23: 345–355.
Corson MA, Berk BC. Growth factors and the vessel wall. Heart Dis Stroke 1993; 2 (2): 166–170.
Ross R. The pathogenesis of atherosclerosis—an update. N Engl J Med 1986; 314: 488–500.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer Science+Business Media New York
About this chapter
Cite this chapter
Spanier, T.B., Schmidt, A.M. (1999). Endothelial Cell Injury. In: Oz, M.C., Goldstein, D.J. (eds) Minimally Invasive Cardiac Surgery. Contemporary Cardiology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-4757-3036-4_3
Download citation
DOI: https://doi.org/10.1007/978-1-4757-3036-4_3
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-61737-108-0
Online ISBN: 978-1-4757-3036-4
eBook Packages: Springer Book Archive